Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma

被引:6
作者
Yang, Qin [1 ]
Zhu, Weiyuan [1 ]
Gong, Han [2 ,3 ]
机构
[1] Shaoyang Univ, Affiliated Hosp 1, Sch Basic Med, Shaoyang, Hunan, Peoples R China
[2] Cent South Univ, Mol Biol Res Ctr, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Ctr Med Genet, Sch Life Sci, Changsha, Hunan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
immunity; lung adenocarcinoma; mutation; predictive risk model; T cell proliferation-related regulator genes; tumor microenvironment; TUMOR; IMMUNOTHERAPY; INHIBITOR; CANCER; CHALLENGES; BURDEN;
D O I
10.3389/fimmu.2023.1148483
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundLung adenocarcinoma (LUAD), the major lung cancer histotype, represents 40% lung cancers. Currently, outcomes are remarkably different in LUAD patients with similar AJCC/UICC-TNM features. T cell proliferation-related regulator genes (TPRGs) relate to the proliferation, activity and function of T cells and tumor progression. The values of TPRGs in classifying LUAD patients and predicting outcomes remain unknown. MethodsGene expression profile and corresponding clinical data were downloaded from TCGA and the GEO databases. We systematically analyzed the expression profile characteristics of 35 TPRGs in LUAD patients and investigated the differences in overall survival (OS), biology pathway, immunity and somatic mutation between different TPRGs-related subtypes. Subsequently, we constructed a TPRGs-related risk model in TCGA cohort to quantify risk scores using LASSO cox regression analysis and then validated this risk model in two GEO cohorts. LUAD patients were divided into high- and low-risk subtypes according to the median risk score. We systematically compared the biology pathway, immunity, somatic mutation and drug susceptibility between the two risk subtypes. Finally, we validate biological functions of two TPRGs-encoded proteins (DCLRE1B and HOMER1) in LUAD cells A549. ResultsWe identified different TPRGs-related subtypes (including cluster 1/cluster A and its counterpart cluster 2/cluster B). Compared to the cluster 1/cluster A subtype, cluster 2/cluster B subtype tended to have a prominent survival advantage with an immunosuppressive microenvironment and a higher somatic mutation frequency. Then, we constructed a TPRGs-related 6-gene risk model. The high-risk subtype characterized by higher somatic mutation frequency and lower immunotherapy response had a worse prognosis. This risk model was an independent prognostic factor and showed to be reliable and accurate for LUAD classification. Furthermore, subtypes with different risk scores were significantly associated with drug sensitivity. DCLRE1B and HOMER1 suppressed cell proliferation, migration and invasion in LUAD cells A549, which was in line with their prognostic values. ConclusionWe construed a novel stratification model of LUAD based on TPRGs, which can accurately and reliably predict the prognosis and might be used as a predictive tool for LUAD patients.
引用
收藏
页数:18
相关论文
共 54 条
  • [1] MUC16 as a novel target for cancer therapy
    Aithal, Abhijit
    Rauth, Sanchita
    Kshirsagar, Prakash
    Shah, Ashu
    Lakshmanan, Imayavaramban
    Junker, Wade M.
    Jain, Maneesh
    Ponnusamy, Moorthy P.
    Batra, Surinder K.
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (08) : 675 - 686
  • [2] The lung microenvironment: an important regulator of tumour growth and metastasis
    Altorki, Nasser K.
    Markowitz, Geoffrey J.
    Gao, Dingcheng
    Port, Jeffrey L.
    Saxena, Ashish
    Stiles, Brendon
    McGraw, Timothy
    Mittal, Vivek
    [J]. NATURE REVIEWS CANCER, 2019, 19 (01) : 9 - 31
  • [3] Targeting Epigenetics to Prevent Obesity Promoted Cancers
    Berger, Nathan A.
    Scacheri, Peter C.
    [J]. CANCER PREVENTION RESEARCH, 2018, 11 (03) : 125 - 128
  • [4] The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer
    Bremnes, Roy M.
    Busund, Lill-Tove
    Kilvaer, Thomas L.
    Andersen, Sigve
    Richardsen, Elin
    Paulsen, Erna Elise
    Hald, Sigurd
    Khanehkenari, Mehrdad Rakaee
    Cooper, Wendy A.
    Kao, Steven C.
    Donnem, Tom
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 789 - 800
  • [5] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    Chan, T. A.
    Yarchoan, M.
    Jaffee, E.
    Swanton, C.
    Quezada, S. A.
    Stenzinger, A.
    Peters, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (01) : 44 - 56
  • [6] TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
    Colaprico, Antonio
    Silva, Tiago C.
    Olsen, Catharina
    Garofano, Luciano
    Cava, Claudia
    Garolini, Davide
    Sabedot, Thais S.
    Malta, Tathiane M.
    Pagnotta, Stefano M.
    Castiglioni, Isabella
    Ceccarelli, Michele
    Bontempi, Gianluca
    Noushmehr, Houtan
    [J]. NUCLEIC ACIDS RESEARCH, 2016, 44 (08) : e71
  • [7] MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
    Felder, Mildred
    Kapur, Arvinder
    Gonzalez-Bosquet, Jesus
    Horibata, Sachi
    Heintz, Joseph
    Albrecht, Ralph
    Fass, Lucas
    Kaur, Justanjyot
    Hu, Kevin
    Shojaei, Hadi
    Whelan, Rebecca J.
    Patankar, Manish S.
    [J]. MOLECULAR CANCER, 2014, 13
  • [8] Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
    Genova, Carlo
    Dellepiane, Chiara
    Carrega, Paolo
    Sommariva, Sara
    Ferlazzo, Guido
    Pronzato, Paolo
    Gangemi, Rosaria
    Filaci, Gilberto
    Coco, Simona
    Croce, Michela
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 12
  • [9] Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
    Guo, Xinyi
    Zhang, Yuanyuan
    Zheng, Liangtao
    Zheng, Chunhong
    Song, Jintao
    Zhang, Qiming
    Kang, Boxi
    Liu, Zhouzerui
    Jin, Liang
    Xing, Rui
    Gao, Ranran
    Zhang, Lei
    Dong, Minghui
    Hu, Xueda
    Ren, Xianwen
    Kirchhoff, Dennis
    Roider, Helge Gottfried
    Yan, Tiansheng
    Zhang, Zemin
    [J]. NATURE MEDICINE, 2018, 24 (07) : 978 - +
  • [10] GSVA: gene set variation analysis for microarray and RNA-Seq data
    Haenzelmann, Sonja
    Castelo, Robert
    Guinney, Justin
    [J]. BMC BIOINFORMATICS, 2013, 14